Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs LORFAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.
Treatment of opioid dependence (FDA-approved),Maintenance therapy for opioid use disorder,Off-label: chronic pain management (limited use)
FDA-approved for treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on prior ALK inhibitors,Off-label: ROS1-positive metastatic NSCLC
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Terminal elimination half-life is 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in severe impairment).
Buprenorphine is primarily metabolized by CYP3A4 to norbuprenorphine; naloxone is metabolized by UDP-glucuronosyltransferases (UGT1A1, UGT1A3).
Primarily metabolized by CYP3A4 and UGT1A4. Lorlatinib is a substrate of P-glycoprotein.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Primarily renal excretion (90-95% as unchanged drug); minimal biliary/fecal elimination (<5%).
Buprenorphine: ~96% bound to alpha- and beta-globulins; naloxone: ~45% bound to albumin (primarily).
Approximately 20-30% bound to plasma proteins, primarily albumin.
Buprenorphine: Vd ~2.5-4.0 L/kg (large distribution due to lipophilicity); naloxone: Vd ~2.0 L/kg.
2.0-3.0 L/kg, indicating extensive distribution into tissues.
Sublingual buprenorphine: ~30-50% (avoid first-pass); sublingual naloxone: ~10% (low); IV: 100% both.
Subcutaneous: approximately 80-100%; intramuscular: approximately 80%; intravenous: 100%.
For GFR <30 m L/min: use with caution, dose reduction may be necessary; avoid in severe impairment (creatinine clearance <15 m L/min) due to naloxone accumulation.
No adjustment required for GFR ≥ 30 m L/min; avoid use if GFR < 30 m L/min.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50%, monitor for oversedation. Child-Pugh Class C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce to 12 mg once daily; Child-Pugh Class C: not recommended.
Not approved for pediatric patients under 16 years for opioid use disorder; safety and efficacy not established.
Not established for age < 18 years.
Initiate at lower end of dosing range (e.g., 2/0.5 mg sublingually once daily) due to increased sensitivity and potential for hepatic/renal impairment; titrate slowly and monitor for CNS depression.
No specific dose adjustment; monitor renal function and tolerability closely due to age-related decline in renal function.
Risk of respiratory depression, particularly in patients using other CNS depressants, and risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression risk with intravenous administration,Hepatotoxicity (elevated liver enzymes, hepatic failure),Adrenal insufficiency with chronic use,Interaction with benzodiazepines and other CNS depressants,Precipitation of withdrawal in opioid-dependent patients if administered too soon after last opioid use,Dependence and abuse potential (Schedule III controlled substance),Neonatal opioid withdrawal syndrome if used during pregnancy
Hepatotoxicity: Monitor liver enzymes monthly for first 3 months, then periodically.,Interstitial lung disease/pneumonitis: Withhold and evaluate.,Hyperlipidemia: Monitor serum cholesterol and triglycerides; manage with lipid-lowering agents.,CNS effects: Including seizure, hallucinations, cognitive impairment; dose adjust or withhold.,AV block: Monitor ECG; withhold in second- or third-degree AV block.,Fetal harm: Can cause fetal harm; advise effective contraception.
Hypersensitivity to buprenorphine or naloxone,Severe respiratory insufficiency (e.g., acute asthma, COPD),Severe hepatic impairment,Patients with acute intoxication (alcohol, opioids, benzodiazepines),Concurrent use of MAO inhibitors (relative contraindication)
Concomitant use of strong CYP3A4 inducers,Concomitant use of strong CYP3A4 inhibitors (avoid, or reduce dose if unavoidable)
No significant food interactions; grapefruit juice may increase buprenorphine levels but not considered clinically relevant; alcohol is contraindicated due to additive CNS depression; take on an empty stomach or with food if GI upset occurs.
Take on empty stomach with water only. Must follow a low-fat diet (<20% of total calories from fat) throughout treatment. Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). Avoid alcohol due to hepatotoxicity risk.
Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use. No known specific teratogenicity; however, maternal opioid use may lead to fetal growth restriction, preterm birth, and stillbirth. Buprenorphine/naloxone is preferred over methadone in pregnancy due to less neonatal respiratory depression and NOWS severity.
Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal exposures below human AUC. No human data. Avoid in pregnancy; if used, advise effective contraception.
Limited data; buprenorphine and naloxone are excreted into breast milk in low concentrations. The M/P ratio for buprenorphine is approximately 0.5–2.5, with high interindividual variability. Naloxone has poor oral bioavailability, reducing infant exposure. Benefits of breastfeeding likely outweigh risks if mother is stable on treatment. Monitor infant for sedation, respiratory depression, and adequate weight gain. Avoid use during breastfeeding in cases of high maternal doses or concurrent substance abuse.
No human data on lorlatinib in breast milk. Animal studies show excretion in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise not to breastfeed during treatment and for at least 11 days after last dose.
Pregnancy may require dose increases due to increased plasma volume, enhanced clearance, and changes in protein binding. Buprenorphine is extensively metabolized by CYP3A4, which may be induced during pregnancy. Aim to maintain trough levels to prevent withdrawal. Usually, doses are adjusted based on clinical response (withdrawal symptoms, cravings). No fixed dose adjustment; individual titration is necessary. Higher doses (up to 50% increase) may be needed in late pregnancy. Postpartum, doses should be tapered back to prepregnancy levels gradually.
Physiologic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) may reduce lorlatinib exposure. Monitor therapeutic response and toxicity. Consider dose adjustment based on tolerability (increase if subtherapeutic, but safety not established). No specific dose recommendations due to lack of human data; hold if severe toxicity.
Avoid in patients with known respiratory insufficiency or acute opioid intoxication; use with caution in hepatic impairment; buprenorphine has a ceiling effect for respiratory depression; naloxone component prevents IV abuse; monitor for precipitated withdrawal if initiated too soon after last opioid use; requires at least 12 hours since last short-acting opioid or 24-72 hours for long-acting opioids; can cause QT prolongation at high doses; sublingual absorption is critical; consider dose adjustment in renal impairment.
LORFAN (lomitapide) is a microsomal triglyceride transfer protein inhibitor used for homozygous familial hypercholesterolemia. Monitor hepatic function monthly due to risk of elevated transaminases and hepatic steatosis. Must be taken with a low-fat diet (<20% of calories from fat) to reduce gastrointestinal adverse effects. Concomitant use with strong CYP3A4 inhibitors is contraindicated. Dose adjustments needed with moderate CYP3A4 inhibitors. Administer with water only, no food, at least 2 hours after evening meal and 2 hours before next meal.
Place the tablet/film under the tongue until fully dissolved; do not chew, swallow, or crush.,Do not use alcohol or other sedatives (benzodiazepines, muscle relaxants, sleeping pills) as this can cause severe respiratory depression or coma.,Keep out of reach of children and pets; accidental ingestion is life-threatening.,Avoid driving or operating machinery until you know how the medication affects you.,Do not stop suddenly; withdrawal symptoms can occur; taper under medical supervision.,Store at room temperature away from moisture and heat.,Tell all healthcare providers you are taking this medication before any surgery or new prescriptions.,Seek emergency help if you experience difficulty breathing, chest pain, or signs of allergic reaction (rash, swelling).,If you miss a dose, skip it; do not double dose.
Take lomitapide with a low-fat diet; avoid high-fat meals to reduce stomach side effects.,Take the medication with a glass of water only, at least 2 hours after your evening meal and 2 hours before your next meal.,Do not eat grapefruit or drink grapefruit juice while taking this medication.,Inform your doctor immediately if you experience yellowing of eyes/skin, dark urine, or abdominal pain.,You will need regular blood tests to check liver function; do not miss these appointments.,Avoid alcohol consumption during treatment.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs LORFAN, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.. LORFAN is a Opioid antagonist that works by Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and LORFAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is: Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.. The standard adult dose of LORFAN is: 12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and LORFAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Secon. LORFAN is classified as Category C. Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.